Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses.

Lavin Y, Kobayashi S, Leader A, Amir ED, Elefant N, Bigenwald C, Remark R, Sweeney R, Becker CD, Levine JH, Meinhof K, Chow A, Kim-Shulze S, Wolf A, Medaglia C, Li H, Rytlewski JA, Emerson RO, Solovyov A, Greenbaum BD, Sanders C, Vignali M, Beasley MB, Flores R, Gnjatic S, Pe'er D, Rahman A, Amit I, Merad M.

Cell. 2017 May 4;169(4):750-765.e17. doi: 10.1016/j.cell.2017.04.014.

2.

Determination of poor prognostic immune features of tumour microenvironment in non-smoking patients with lung adenocarcinoma.

Kinoshita T, Kudo-Saito C, Muramatsu R, Fujita T, Saito M, Nagumo H, Sakurai T, Noji S, Takahata E, Yaguchi T, Tsukamoto N, Hayashi Y, Kaseda K, Kamiyama I, Ohtsuka T, Tomizawa K, Shimoji M, Mitsudomi T, Asamura H, Kawakami Y.

Eur J Cancer. 2017 Nov;86:15-27. doi: 10.1016/j.ejca.2017.08.026. Epub 2017 Sep 23.

PMID:
28950145
3.

Non-small cell lung cancer induces an immunosuppressive phenotype of dendritic cells in tumor microenvironment by upregulating B7-H3.

Schneider T, Hoffmann H, Dienemann H, Schnabel PA, Enk AH, Ring S, Mahnke K.

J Thorac Oncol. 2011 Jul;6(7):1162-8. doi: 10.1097/JTO.0b013e31821c421d.

4.

The prognostic landscape of tumor-infiltrating immune cell and immunomodulators in lung cancer.

Liu X, Wu S, Yang Y, Zhao M, Zhu G, Hou Z.

Biomed Pharmacother. 2017 Nov;95:55-61. doi: 10.1016/j.biopha.2017.08.003. Epub 2017 Aug 18.

PMID:
28826097
5.

CD4+CXCR4highCD69+ T cells accumulate in lung adenocarcinoma.

Wald O, Izhar U, Amir G, Avniel S, Bar-Shavit Y, Wald H, Weiss ID, Galun E, Peled A.

J Immunol. 2006 Nov 15;177(10):6983-90.

6.

Adenocarcinoma contains more immune tolerance regulatory t-cell lymphocytes (versus squamous carcinoma) in non-small-cell lung cancer.

Black CC, Turk MJ, Dragnev K, Rigas JR.

Lung. 2013 Jun;191(3):265-70. doi: 10.1007/s00408-013-9455-7. Epub 2013 Mar 15.

PMID:
23494387
7.

Lung Adenocarcinoma and Squamous Cell Carcinoma Gene Expression Subtypes Demonstrate Significant Differences in Tumor Immune Landscape.

Faruki H, Mayhew GM, Serody JS, Hayes DN, Perou CM, Lai-Goldman M.

J Thorac Oncol. 2017 Jun;12(6):943-953. doi: 10.1016/j.jtho.2017.03.010. Epub 2017 Mar 21.

8.

Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells.

Goc J, Germain C, Vo-Bourgais TK, Lupo A, Klein C, Knockaert S, de Chaisemartin L, Ouakrim H, Becht E, Alifano M, Validire P, Remark R, Hammond SA, Cremer I, Damotte D, Fridman WH, Sautès-Fridman C, Dieu-Nosjean MC.

Cancer Res. 2014 Feb 1;74(3):705-15. doi: 10.1158/0008-5472.CAN-13-1342. Epub 2013 Dec 23.

9.

An Immunogram for the Cancer-Immunity Cycle: Towards Personalized Immunotherapy of Lung Cancer.

Karasaki T, Nagayama K, Kuwano H, Nitadori JI, Sato M, Anraku M, Hosoi A, Matsushita H, Morishita Y, Kashiwabara K, Takazawa M, Ohara O, Kakimi K, Nakajima J.

J Thorac Oncol. 2017 May;12(5):791-803. doi: 10.1016/j.jtho.2017.01.005. Epub 2017 Jan 11.

10.

Differential innate immune cell signatures and effects regulated by toll-like receptor 4 during murine lung tumor promotion.

Alexander CM, Xiong KN, Velmurugan K, Xiong J, Osgood RS, Bauer AK.

Exp Lung Res. 2016 Apr;42(3):154-73. doi: 10.3109/01902148.2016.1164263.

11.

Epithelial-Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma.

Lou Y, Diao L, Cuentas ER, Denning WL, Chen L, Fan YH, Byers LA, Wang J, Papadimitrakopoulou VA, Behrens C, Rodriguez JC, Hwu P, Wistuba II, Heymach JV, Gibbons DL.

Clin Cancer Res. 2016 Jul 15;22(14):3630-42. doi: 10.1158/1078-0432.CCR-15-1434. Epub 2016 Feb 5.

12.

Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non-Small Cell Lung Cancer.

Li B, Cui Y, Diehn M, Li R.

JAMA Oncol. 2017 Nov 1;3(11):1529-1537. doi: 10.1001/jamaoncol.2017.1609.

13.

HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma.

Zheng H, Zhao W, Yan C, Watson CC, Massengill M, Xie M, Massengill C, Noyes DR, Martinez GV, Afzal R, Chen Z, Ren X, Antonia SJ, Haura EB, Ruffell B, Beg AA.

Clin Cancer Res. 2016 Aug 15;22(16):4119-32. doi: 10.1158/1078-0432.CCR-15-2584. Epub 2016 Mar 10.

14.

[Clinical significance of T lymphocyte subset changes after first line chemotherapy in peripheral blood from patients with advanced stage adenocarcinoma cell lung cancer].

Yan X, Zhao X, Jiao S, Sun S, Wu L, Wu Z.

Zhongguo Fei Ai Za Zhi. 2012 Mar;15(3):164-71. doi: 10.3779/j.issn.1009-3419.2012.03.06. Chinese.

15.

Comprehensive Immune Profiling of Lung Adenocarcinomas Reveals Four Immunosubtypes with Plasma Cell Subtype a Negative Indicator.

Kurebayashi Y, Emoto K, Hayashi Y, Kamiyama I, Ohtsuka T, Asamura H, Sakamoto M.

Cancer Immunol Res. 2016 Mar;4(3):234-47. doi: 10.1158/2326-6066.CIR-15-0214. Epub 2016 Jan 19.

16.

Programmed Death Ligand-1 (PD-L1) Expression in Either Tumor Cells or Tumor-Infiltrating Immune Cells Correlates With Solid and High-Grade Lung Adenocarcinomas.

Driver BR, Miller RA, Miller T, Deavers M, Gorman B, Mody D, Ge Y, Barrios R, Bernicker E, Kim M, Cagle PT.

Arch Pathol Lab Med. 2017 Nov;141(11):1529-1532. doi: 10.5858/arpa.2017-0028-OA. Epub 2017 Aug 22.

PMID:
28829153
17.

Intratumoral Immune Cell Densities Are Associated with Lung Adenocarcinoma Gene Alterations.

Mansuet-Lupo A, Alifano M, Pécuchet N, Biton J, Becht E, Goc J, Germain C, Ouakrim H, Régnard JF, Cremer I, Laurent-Puig P, Dieu-Nosjean MC, Blons H, Damotte D.

Am J Respir Crit Care Med. 2016 Dec 1;194(11):1403-1412.

PMID:
27299180
18.

Tumor-infiltrating regulatory T cells inhibit endogenous cytotoxic T cell responses to lung adenocarcinoma.

Ganesan AP, Johansson M, Ruffell B, Yagui-Beltrán A, Lau J, Jablons DM, Coussens LM.

J Immunol. 2013 Aug 15;191(4):2009-17. doi: 10.4049/jimmunol.1301317. Epub 2013 Jul 12. Erratum in: J Immunol. 2013 Nov 15;191(10):5319. Beltran, Adam [corrected to Yagui-Beltrán, Adam].

19.

Foxp3(+) regulatory T cells and natural killer cells distinctly infiltrate primary tumors and draining lymph nodes in pulmonary adenocarcinoma.

Schneider T, Kimpfler S, Warth A, Schnabel PA, Dienemann H, Schadendorf D, Hoffmann H, Umansky V.

J Thorac Oncol. 2011 Mar;6(3):432-8. doi: 10.1097/JTO.0b013e31820b80ca.

20.

Immune Atlases Created for Kidney, Lung Cancers.

[No authors listed]

Cancer Discov. 2017 Jul;7(7):658-659. doi: 10.1158/2159-8290.CD-NB2017-075. Epub 2017 May 25.

Supplemental Content

Support Center